Mumbai: IOL Chemicals and Pharmaceuticals Ltd (IOLCP), a leading manufacturer of pharmaceutical APIs and specialty chemicals, has announced its unaudited financial results for the quarter ended 30th June 2025.
Standalone Q1 FY26 Financial Highlights (₹ in Crore)
| Particulars | Q1 FY26 | Q4 FY25 | % QoQ | Q1 FY24 | % YoY |
| Total Income | 559.06 | 532.30 | 5.0 | 509.76 | 9.7 |
| EBITDA | 63.54 | 61.40 | 3.5 | 58.23 | 9.1 |
| EBITDA Margin (%) | 11.4% | 11.5% | -10 bps | 11.4% | 0 bps |
| PAT | 33.96 | 31.62 | 7.4 | 29.68 | 14.4 |
| PAT Margin (%) | 6.1% | 5.9% | 20 bps | 5.8% | 30 bps |
Key Business Updates for the Quarter
- Overseas Expansion: Formation of a wholly owned subsidiary in the United Kingdom to strengthen presence in the UK and EU markets and enable better customer access.
- New Project Announcement: The Company has approved the establishment of Unit 9B, carved out from the existing Unit 9, dedicated to manufacturing Minoxidil and its intermediates. The unit will have an installed capacity of 120 MTPA, with a planned capital expenditure of ₹5.5 crore, fully funded through internal accruals. Completion is expected by December 2025.
Leave a Reply